Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Citalopram
Drug ID BADD_D00475
Description Citalopram belongs to a class of antidepressant agents known as selective _serotonin-reuptake inhibitors_ (SSRIs) and is widely used to treat the symptoms of depression. Its chemical structure is unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other prescribed antidepressants [FDA label]. Citalopram is also known as _Celexa_, and available in tablet and solution forms [FDA label]. This drug was initially approved by the FDA in 1998 [L5230].
Indications and Usage For the treatment of depression. Off-label indications include: treatment of mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA label].
Marketing Status Prescription
ATC Code N06AB04
DrugBank ID DB00215
KEGG ID D07704
MeSH ID D015283
PubChem ID 2771
TTD Drug ID D0Y5DO
NDC Product Code 69097-823; 42806-020; 70518-0561; 43063-385; 43353-112; 70518-2228; 65162-054; 67046-102; 71610-092; 0456-4020; 50090-5170; 69097-824; 68788-7899; 70518-2617; 43063-063; 70934-539; 65162-052; 54458-980; 69097-822; 70518-2553; 0054-0062; 52427-691; 60429-174; 67046-106; 76282-629; 61919-390; 76282-628; 50090-5172; 54458-889; 70518-2601; 70518-2671; 54458-981; 0378-6233; 71335-0541; 60429-173; 71610-412; 63850-3616; 65162-053; 0378-6231; 0456-4010; 42806-021; 76282-206; 68071-3034; 67046-101; 70518-0449; 60429-175; 70934-397; 43353-208; 50090-5175; 63629-6761; 0456-4040; 61919-389; 76282-208; 71610-422; 80425-0093; 76282-207; 0378-6232; 43353-091; 42806-019
Synonyms Citalopram | Cytalopram | Citalopram Hydrobromide | Lu-10-171 | Lu10171 | Seropram | Celexa
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 59729-33-8
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Arrhythmia supraventricular02.03.03.0010.000125%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.0010.000250%
Arthropathy15.01.01.003--Not Available
Ascites09.01.05.003; 07.07.01.001; 02.05.04.002--
Aspartate aminotransferase increased13.03.01.0060.000542%
Asphyxia22.02.02.001; 12.01.08.0110.000174%Not Available
Asthenia08.01.01.001--Not Available
Asthenopia06.01.01.0020.000083%Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrial fibrillation02.03.03.002--
Atrial septal defect03.07.02.002; 02.04.02.0090.003041%Not Available
Atrioventricular block first degree02.03.01.0040.000125%
Atrioventricular block second degree02.03.01.0050.000083%
Attention deficit/hyperactivity disorder19.21.04.0010.000083%Not Available
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.010--Not Available
Back pain15.03.04.005--
Bladder dilatation20.03.01.0070.000033%Not Available
Bladder irritation20.02.02.0200.000167%Not Available
Bladder pain20.02.02.001--Not Available
Blindness06.02.02.001; 17.17.01.003--Not Available
Blindness unilateral17.17.01.016; 06.02.02.0090.000167%Not Available
Blood calcium decreased13.11.01.0020.000208%Not Available
Blood creatine phosphokinase increased13.04.01.0010.000417%
Blood creatinine increased13.13.01.004--
Blood glucose increased13.02.02.002--Not Available
Blood lactate dehydrogenase increased13.04.02.0020.000333%
Blood magnesium decreased13.11.01.0080.000125%Not Available
Blood potassium decreased13.11.01.0100.000208%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 37 Pages